Fanconi anemia complementation group P
MONDO:0013499Any Fanconi anemia in which the cause of the disease is a mutation in the SLX4 gene.
Also known as: FANCP, Fanconi Anemia, complementation group type P, Fanconi anaemia caused by mutation in SLX4, Fanconi anaemia caused by mutation in Slx4, Fanconi anaemia complementation group type P, Fanconi anemia caused by mutation in SLX4, Fanconi anemia caused by mutation in Slx4, Fanconi anemia complementation group type P
12 clinical trials for this condition and its sub-types, 0 tagged with Fanconi anemia complementation group P itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New combo therapy targets cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase 3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC